Diabetic Patients With Newly Diagnosed Chronic Myeloid Leukemia: TKI Choice and Early Adverse Events. A Real‐Life Survey Within the Italian Chronic Myeloid Leukemia Network

医学 中止 髓系白血病 内科学 尼罗替尼 糖尿病 相伴的 入射(几何) 不利影响 共病 队列 伊马替尼 二甲双胍 甲磺酸伊马替尼 队列研究 髓样 病人登记处 回顾性队列研究 肿瘤科 慢性白血病
作者
S. Russo,Isabella Capodanno,Mario Tiribelli,Maria Cristina Miggiano,Daniele Cattaneo,F. Cavazzini,S. Leonetti Crescenzi,E. Scalzulli,A. Bernardelli,Luigia Luciano,Olga Mulas,G. Loglisci,C. Elena,G.L. Morelli,Immacolata Attolico,Gianni Binotto,E. Crisà,Paolo Sportoletti,A. Di Veroli,A. R. Scortechini
出处
期刊:European Journal of Haematology [Wiley]
标识
DOI:10.1111/ejh.70268
摘要

ABSTRACT Limited data are available regarding patients with newly diagnosed chronic myeloid leukemia (CML) and concomitant diabetes mellitus (DM). Hence, we retrospectively analyzed 2149 patients with newly diagnosed chronic phase (CP) CML to compare clinical characteristics, choice of frontline therapy, early adverse events, and molecular responses between patients with or without DM. Among this cohort of 2149 patients, 241 patients (11.2%) had DM at CML diagnosis. Diabetic patients were older (median age 69.6 vs. 58.2 years, p < 0.001), showed a higher Sokal/ELTS risk and had more comorbidities, resulting in more frequent polypharmacy. Imatinib was frequently selected as first‐line treatment in diabetic patients (71% vs. 53%, p < 0.001), whereas nilotinib was more common in nondiabetics (6.2% vs. 31.9%). Discontinuation by the 12th month occurred in 24.2% of diabetic patients versus 19.4% of nondiabetics ( p = 0.031), mainly for hematologic toxicity. Diabetic patients showed a lower incidence of major molecular response (MMR) at the 12th month (55.9% vs. 68.1%, p = 0.002). Among diabetic patients, a trend toward better molecular responses was observed in patients receiving metformin ( p = 0.068). In conclusion, DM represents a clinically meaningful comorbidity in newly diagnosed CML‐CP, and seems to define a subgroup with distinct features, influencing both treatment decisions and early outcomes.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Marksman497完成签到,获得积分10
刚刚
水弘的应助被乐观老三采纳,获得10
刚刚
川一发布了新的文献求助10
1秒前
深情雪珊发布了新的文献求助10
1秒前
Swuliu发布了新的文献求助10
1秒前
2秒前
2秒前
3秒前
vc的应助被suer采纳,获得30
3秒前
兔兔兔兔兔完成签到,获得积分10
3秒前
花谢完成签到 ,获得积分10
3秒前
Marksman497发布了新的文献求助10
4秒前
勤奋甜瓜完成签到 ,获得积分10
5秒前
6秒前
坦率灵槐完成签到,获得积分10
6秒前
6秒前
璇璇完成签到,获得积分10
6秒前
lxf完成签到,获得积分10
8秒前
烂漫元彤发布了新的文献求助10
8秒前
传奇3的应助被yebo采纳,获得10
8秒前
赘婿的应助被九号球采纳,获得10
9秒前
DW的应助被麦粑块采纳,获得10
9秒前
Orange的应助被十点熄灯采纳,获得10
9秒前
zkylh的应助被麦粑块采纳,获得10
9秒前
bkagyin的应助被麦粑块采纳,获得10
10秒前
科研通AI6.3的应助被麦粑块采纳,获得10
10秒前
桐桐的应助被麦粑块采纳,获得10
10秒前
秋风的应助被麦粑块采纳,获得10
10秒前
领导范儿的应助被麦粑块采纳,获得10
10秒前
饺饺者完成签到,获得积分10
12秒前
12秒前
啦啦啦发布了新的文献求助10
13秒前
生半夏发布了新的文献求助10
13秒前
JvvJ完成签到 ,获得积分10
13秒前
14秒前
一颗苹果的应助被牧百川采纳,获得10
15秒前
15秒前
顾矜的应助被Swuliu采纳,获得10
16秒前
16秒前
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183381
求助须知:如何正确求助?哪些是违规求助? 9572627
关于积分的说明 21826833
捐赠科研通 7780405
什么是DOI,文献DOI怎么找? 3433993
关于科研通互助平台的介绍 2558177
邀请新用户注册赠送积分活动 2480309